Beta 2 adrenergic receptor agonists are a class of medications that activate the beta 2 adrenergic receptors in the body. These receptors are predominantly found in smooth muscle tissues, particularly in the lungs. The mechanism of action of beta 2 adrenergic receptor agonists involves binding to these receptors, which leads to relaxation of the smooth muscles in the airways, resulting in bronchodilation. This makes them particularly effective in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization (WHO), respiratory conditions affect a significant number of people globally. In Europe, approximately 235 million people are affected by asthma, and it is estimated that COPD affects around 44 million individuals. In the United States, the Centers for Disease Control and Prevention (CDC) reports that around 25 million people have asthma, while over 16 million adults have been diagnosed with COPD.
The growth drivers of the beta 2 adrenergic receptor agonist market include the increasing prevalence of respiratory diseases, rising awareness and diagnosis rates, advancements in drug formulations and delivery systems, and the growing aging population. These factors contribute to the expanding market for beta 2 adrenergic receptor agonists, as they continue to be crucial medications in managing respiratory conditions and improving patients' quality of life. Companies such as AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Teva, Chiesi, Merck (MSD), Innoviva, Orion Corp, Vectura, Almirall, CuraSen Therap, Intech Biopharm, Evofem Biosci, Otsuka cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, AstraZeneca is one such company currently conducting a clinical trial of the drug Abediterol (AZD-0548) for treating Asthma.
Key Developments
- In September 2019, GSK launched Anoro Ellipta for Chronic obstructive pulmonary disease in Italy
- In September 2021, Boehringer Ingelheim launched Spiolto Respimat for Chronic obstructive pulmonary disease in France, Greece, Hungary, Portugal, Belgium, New Zealand, Israel, Germany, Sweden, Poland, Chile, Russia, Philippines, Netherlands, Czech Republic, Indonesia, Hong Kong, Argentina, Switzerland, Turkey, Mexico, Singapore, Ukraine
Approved Beta 2 Adrenergic Receptor Agonist molecules
- Fluticasone propionate, salmeterol xinafoate inhalation powder
- Budesonide, formoterol
- Breo Ellipta (fluticasone furoate , vilanterol)
- Onbrez (indacaterol)
- Ventolin (albuterol)
- Albuterol sulfate
- Stiolto Respimat (olodaterol, tiotropium FDC)
- Anoro Ellipta (umeclidinium, vilanterol)
- Beclometasone, formoterol
- Ultibro (glycopyrronium, indacaterol)
- Striverdi Respimat (olodaterol)
- Riarify (beclometasone, formoterol, glycopyrrolate)
- Albuterol sulfate inhalation aerosol
- Levalbuterol
- Flutiform (fluticasone, formoterol)
- Breztri Aerosphere (budesonide, formoterol fumarate, glycopyrronium)
- Trelegy Ellipta (fluticasone furoate, umeclidinium bromide, vilanterol)
- Combivent (ipratropium, salbutamol)
- Bevespi Aerosphere (formoterol, glycopyrrolate)
- Dulera (mometasone, formoterol)
- Foradil Aerolizer (formoterol dry powder inhaler)
- Arformoterol
- Terbutaline oral
- Atectura Breezhaler (indacaterol, mometasone furoate)
- Berodual N (ipratropium bromide, fenoterol hydrobromide)
- Proventil (albuterol)
- Atimos (formoterol hydrofluoroalkane inhaler) , Chiesi ,
- Bufomix Easyhaler (budesonide, formoterol dry powder inhaler)
- Oxis Turbuhaler (formoterol)
- Xopenex HFA (levalbuterol tartrate)
- Oxeze Turbuhaler (formoterol dry-powder inhaler)
- Enerzair Breezhaler (glycopyrrolate, indacaterol, mometasone)
- Fenoterol
- Airsupra (budesonide, salbutamol)
- DuoResp Spiromax (budesonide, formoterol)
- Formoterol fumarate
- Advair HFA (salmeterol xinafoate, fluticasone propionate inhalation aerosol)
- HOKUNALIN patch (tulobuterol)
- Serevent Diskhaler (salmeterol dry-powder inhaler)
- Ventmax SR (salbutamol sulphate)
- Albuterol inhaled aerosol
- Salmeterol, fluticasone easyhaler
- Alenia (budesonide, formoterol)
- Salbutamol, beclomethasone
- Bambec (bambuterol)
- Combivent Respimat (ipratropium, albuterol metered spray inhalation)
- Edsivo (celiprolol)
- Formoterol, fluticasone
- Meptin Tablet (procaterol)
- Proair digihaler (albuterol sulfate)
- Duoneb (ipratropium bromide, albuterol sulfate)
- Ipralev (ipratropium, levosalbutamol)
- ProAir Respiclick (albuterol sulfate inhalation powder)
- Synflutide (fluticasone, salmeterol)
- Ciclesonide, formoterol
- AirDuo Digihaler (salmeterol, fluticasone proprionate)
- Buventol Easyhaler (salbutamol dry-powder inhaler)
- Chronodyne (terbutaline vaginal gel)
- Meptin Swinghaler (procaterol)
Beta 2 Adrenergic Receptor Agonist Pipeline Molecules
- Formoterol fumarate (PT005)
- Vilanterol (GW642444H)
- Budesonide, formoterol (PT009)
- Batefenterol (GSK961081)
- Abediterol (AZD-0548)
- Albuterol sulfate metered dose inhaler (PT007)
- Salmeterol xinafoate (LIPO-202)
- AZD3199
- Salmeterol xinafoate, fluticasone propionate (LIPO 102)
- Albuterol inhalational powder (A006 DPI)
- Bedoradrine (KUR-1246)
- Navafenterol (AZD8871)
- Salbutamol (ASF-1096)
- Nadolol (CST-107)
- CST-2032
- Budesonide, carmmonteoterol (CHF 5188)
- Fluticasone, batefenterol (FF, GSK-961081)
- Nadolol oral (INV102 oral)
- Budesonide, formotenol (SYN010)
- ATR-258
- AZD8999
- CHF6366
- Albuterol sufate DPI (TBS-7)
- Terbutaline modified-release (SKP-1052)
Clinical Activity and Development of Beta 2 Adrenergic Receptor Agonist
In the Beta 2 Adrenergic Receptor Agonist space, more than 30 companies are conducting around 800 clinical trials in this category of drugs. For instance,
- In April 2023, GSK presented interim efficacy data of Breo Ellipta from a phase III captain trial in asthma at the 117th International Conference of the American Thoracic Society
- In May 2022, GlaxoSmithKline completed a phase III trial of Fluticasone furoate in Asthma (In children, In adolescents) in the US, Argentina, China, Canada, Japan, Mexico, Romania, Russia, South Africa, Poland, Lithuania, Hungary, Bulgaria, Italy, Germany, and Spain
|
Product Name |
Total Studies |
|
Formoterol fumarate (PT005) |
106 |
|
Vilanterol (GW642444H) |
29 |
|
Budesonide, formoterol (PT009) |
15 |
|
Batefenterol (GSK961081) |
13 |
|
Abediterol (AZD-0548) |
10 |
|
Albuterol sulfate metered dose inhaler (PT007) |
7 |
|
Salmeterol xinafoate (LIPO-202) |
7 |
|
AZD3199 |
6 |
|
Salmeterol xinafoate, fluticasone propionate (LIPO 102) |
6 |
|
qAlbuterol inhalational powder (A006 DPI) |
5 |
|
Bedoradrine (KUR-1246) |
5 |
|
Navafenterol (AZD8871) |
5 |
|
Salbutamol (ASF-1096) |
5 |
|
Nadolol (CST-107) |
4 |
|
CST-2032 |
3 |
|
Budesonide, carmmonteoterol (CHF 5188) |
3 |
|
Fluticasone, batefenterol (FF, GSK-961081) |
3 |
|
Nadolol oral (INV102 oral) |
3 |
Target Indication Analysis of Beta 2 Adrenergic Receptor Agonist
The primary target indication for beta 2 adrenergic receptor agonist drugs is the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). These medications are specifically designed to provide bronchodilation by activating the beta 2 adrenergic receptors in the smooth muscles of the airways. By doing so, they help to relax and widen the air passages, making breathing easier for individuals with respiratory disorders. beta 2 adrenergic receptor agonists are commonly prescribed as short-acting or long-acting inhalers, and they play a crucial role in controlling symptoms, reducing the frequency and severity of asthma attacks, and improving overall lung function in patients with COPD.
Regional Analysis of Beta 2 Adrenergic Receptor Agonist
Beta 2 Adrenergic Receptor Agonist Market
The global beta 2 Adrenergic Receptor Agonist market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The US regional market analysis of beta 2 adrenergic receptor agonists reflects a significant demand and usage of these medications. The United States has a high prevalence of respiratory diseases such as asthma and COPD, which drives the market for beta 2 adrenergic receptor agonists. The market is characterized by the presence of established pharmaceutical companies offering a wide range of medications in this category. Furthermore, there is a growing emphasis on the development of innovative drug formulations and delivery systems to enhance treatment efficacy and patient compliance. The market is also influenced by factors such as healthcare infrastructure, reimbursement policies, and patient awareness programs. Additionally, rising awareness about respiratory conditions and the importance of timely and effective treatment contribute to the growth of the market. Conversely, Canada is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for beta 2 Adrenergic Receptor Agonists. These countries are increasingly adopting beta 2 Adrenergic Receptor Agonists due to their efficacy and potential to improve patient outcomes. On the other hand, the beta 2 Adrenergic Receptor Agonist market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the beta 2 Adrenergic Receptor Agonist market.
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
Beta 2 Adrenergic Receptor Agonist drugs are used in the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
The growth drivers of the beta 2 adrenergic receptor agonist market in the US include the increasing prevalence of respiratory diseases, a large population affected by asthma and COPD, technological advancements in drug delivery systems, and the presence of well-established healthcare infrastructure.
The major players in this space are AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Teva, Chiesi, Merck (MSD), Innoviva, Orion Corp, Vectura, Almirall, CuraSen Therap, Intech Biopharm, Evofem Biosci, Otsuka.
One of the restraints of the beta 2 adrenergic receptor agonist drug market is the potential for side effects associated with these medications, such as tremors, increased heart rate, and decreased potassium levels. These side effects may limit their use in certain patient populations or require close monitoring during treatment. Additionally, the emergence of alternative treatment options and the availability of generic versions of beta 2 adrenergic receptor agonists may pose a competitive challenge to the market, impacting pricing and market share.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- AstraZeneca
- GSK
- Novartis
- Boehringer Ingelheim
- Teva
- Chiesi
- Merck (MSD)
- Innoviva
- Orion Corp
- Vectura
- Almirall
- CuraSen Therap
- Intech Biopharm
- Evofem Biosci
- Otsuka
- Sosei
- Theravance Biopharma
- ASKA Pharma
- Abbott
- Acer Therap
- Acerus
- Ache Lab
- Amphastar
- Ardana Biosci
- Atrogi
- Avillion
- Catalent
- Chronic Airway Therap
- Cipher
- Covis Pharma
- Kissei
- Kyorin
- Maruho
- MediciNova
- Mundipharma
- Neutec
- Nitto Denko
- Sanofi
- Sumitomo Pharma
- Takeda
- Viatris